Skip to the main content.
HUB of
Biotherapeutic
Intelligence™
Protein Manufacturing
Overview

 

Catalog Products
Online Store
HUB of
Biotherapeutic
Intelligence™
See our latest upcoming event.
Tell me moreto Events
HUB of
Biotherapeutic
Intelligence™
Applications
Insights
See our latest upcoming event.
Tell me moreto Events
HUB of
Biotherapeutic
Intelligence™
See our latest upcoming event.
Tell me moreto Events
HUB of
Biotherapeutic
Intelligence™
See our latest upcoming event.
Tell me moreto Events
Ranked #1 CRO1

Target Analysis and Immunization

Contact Us

ENGINEERED for the Scientific Race

Engineered for the biotherapeutic race

Overview

Navigating the right path to achieve your goals— for your specific target 

Choosing the right combination of immunogens, immunization schedules and species mitigates risk and ensures the best outcomes. Based on the characteristics of the antigen and starting material, we can develop peptides, proteins, or antibodies, suitable for customization from multiple immunization platforms.

Services

Target Analysis

At IPA, we know a full understanding of the target protein is critically important to a successful antibody campaign. Expert teams analyze each target and recommend the most effective way to deliver the product you need.

 

Antigen Modeling and Preparation

IPA has developed multiple strategies to select the correct domains of your target antigen (e.g., in silico modelling) and combine these antigens with the optimized immunization routes in different species. Depending on the characteristics of the individual antigen and the available starting material, we either generate synthetic peptides, recombinant proteins, antibodies, or antibody fragments (anti-idiotypic projects), cell lines suitable for immunization (syngeneic), or plasmids for genetic immunization (NonaVacTM). We can further immunize with smaller proteins or whole cell bacteria.

Immunization

A multitude of immunization technologies are available at IPA, ranging from various injection methods to multiple genetic immunization applications to live whole cell-based immunizations.

 

NonaVac™ - DNA

Recommended for complex protein classes, including GPCRs and ion channels as it bypasses the requirement to produce difficult recombinant proteins, and overcomes conformational obstacles of such antigens…

 

Rapid Prime®

Identify positive monoclonal antibodies in as little as 32 days…


 

Syngeneic Cell Line

Immunization of various species with a syngeneic cell line…


Peptide Production

Antigen production at the scale and quality needed for immunization and for seamless use with a subsequent antibody discovery campaign…

Immunization

Proven success

NonaVac™ - DNA

Our genetic immunization protocols have proven successful in the generation of monoclonal antibodies against new, challenging, and conformation-sensitive targets, and have been successfully applied in transgenic animals.

Through our proprietary vectors, our algorithm-based protocols produce native protein with appropriate post-translational modifications in vivo and provide very high transfection efficiency. We recommend this technology for complex protein classes, including GPCRs and ion channels as it bypasses the requirement to produce difficult recombinant proteins, and overcomes conformational obstacles of such antigens. Our vectors are developed in-house and not subject to downstream milestones and royalties.

IPAnonavac

New, challenging, and conformation-sensitive targets

Contact Us

Unmatched efficiency

Rapid Prime®

Rapid Prime identifies positive monoclonal antibodies in as little as 32 days. This method is especially beneficial for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes. Other sources of immunogens include conserved or smaller proteins, peptides, and whole cell bacteria.

After the immunization of rodents, we apply our proprietary electrofusion or PEG-fusion to generate hybridomas. The subsequent cloning, using semi-solid media and clone picking to accelerate the process, allows us to identify monoclonal antibody producing hybridoma cells, fast.

Rapid Prime immunization can also be combined with B cell Select or Phage Display.

IPA Rapid Prime

Positive monoclonal antibodies in as little as 32 days

Contact Us

Various species

Syngeneic Cell Line

Immunization of multiple species with a syngeneic cell line. After the selection of the species for the immunization, we discuss a suitable cell line and prepare transfected cells for immunization and screening.

Premium quality and purity

Peptide Production

The success of your antibody development project is highly dependent on the quality of your antigen. IPA can produce your antigen at the scale and quality needed for immunization and use it seamlessly in a subsequent antibody discovery campaign. 

In the case of anti-peptide projects, the immunizing antigen must be of high purity, enabled for carrier conjugation and safe for injection into animals. Therefore, to help ensure the best start to your antibody development projects, IPA’s scientists assist you in epitope prediction and antigen design. Our peptide production service also includes modifications such as phosphorylations.

Flag France

 

Eligible French companies involved with us in research and development may receive a tax credit. Learn More.

1. ROOTS 2022: Antibody Discovery Services and Platforms Market (4th Edition), 2021-2035; p.118

Your ultimate source for protein production

Online Store


Extensive catalog of antibodies and recombinant proteins, including organoid growth factors: IPA is exclusive producer of WNT Surrogate-Fc fusion protein that is cited in multiple peer review journals.

Go to store

Custom Programs


IPA custom rPEx® production: >8,000 batches of antigens, antibodies, bi- and multi-specific antibodies with >95% purity* — renowned for its flexibility, reliability and efficiency. Discover our excellence. Programs shipped in 8 weeks / 4 weeks for repeat batch production.

Start project

*Historical consolidated average

In silico, in parallel, in an instant

LENSai Integrated Intelligence Technology

Tell Me More

Connect with IPA
Connect with us to solve your greatest biotherapeutic needs